Cary Street Partners Investment Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $183K | Sell |
349
-23
| -6% | -$12.1K | 0.09% | 261 |
|
|
2025
Q1 | $236K | Buy |
372
+6
| +2% | +$3.81K | 0.14% | 181 |
|
|
2024
Q4 | $261K | Sell |
366
-3,708
| -91% | -$2.64M | 0.17% | 136 |
|
|
2024
Q3 | $4.28M | Sell |
4,074
-12
| -0.3% | -$12.6K | 0.16% | 150 |
|
|
2024
Q2 | $4.29M | Buy |
4,086
+696
| +21% | +$731K | 0.17% | 139 |
|
|
2024
Q1 | $3.26M | Buy |
3,390
+302
| +10% | +$291K | 0.14% | 171 |
|
|
2023
Q4 | $2.71M | Buy |
3,088
+427
| +16% | +$375K | 0.13% | 186 |
|
|
2023
Q3 | $2.19M | Buy |
2,661
+450
| +20% | +$370K | 0.12% | 202 |
|
|
2023
Q2 | $1.59M | Buy |
2,211
+1,959
| +777% | +$1.41M | 0.1% | 203 |
|
|
2023
Q1 | $207K | Buy |
252
+140
| +125% | +$115K | 0.01% | 462 |
|
|
2022
Q4 | $80.8K | Buy |
+112
| New | +$80.8K | 0.01% | 635 |
|
|
2022
Q3 | – | Sell |
-192
| Closed | -$113K | – | 552 |
|
|
2022
Q2 | $113K | Buy |
+192
| New | +$113K | 0.01% | 493 |
|
|
2020
Q4 | – | Sell |
-66
| Closed | -$37K | – | 741 |
|
|
2020
Q3 | $37K | Buy |
+66
| New | +$37K | 0.01% | 537 |
|